Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis
Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| miltefosine: 2.5 mg/kg/day for 42 days | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| efficacy |
| Measure | Description | Time Frame |
|---|---|---|
| safety |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jaime Soto, MD | CIBIC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Palos Blancos | Palos Blancos | Bolivia |
Not provided
| ID | Term |
|---|---|
| D007896 | Leishmaniasis |
| ID | Term |
|---|---|
| D056986 | Euglenozoa Infections |
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C039128 | miltefosine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D012876 |
| Skin Diseases, Parasitic |
| D000079426 | Vector Borne Diseases |
| D012874 | Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |